small molecule

MOXIDECTIN

Loss of exclusivityFebruary 2032FDA regulatory exclusivity expiry

CompanyMedicines Development For Global Health →See this company's full patent-cliff portfolio

Drug detail

Brand name	MOXIDECTIN
Active ingredient	MOXIDECTIN
Strength	2MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	June 2018
Marketing status	RX

Regulatory exclusivity

Code	Expires
ODE-528	February 2032
NPP	February 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.